The Asia Renal Denervation Consortium consensus conference of Asian physicians actively
performing renal denervation (RDN) was recently convened to share up-to-date information …

Reports detailing the response of hypertensive patients to renal denervation (RDN) in Asian
patients are limited. We evaluated 6-and 12-month outcomes after RDN in an Asian …

Background: SYMPLICITY HTN-Japan is a prospective, randomized, controlled trial
comparing renal artery denervation (RDN) with standard pharmacotherapy for treatment of …

Hypertension remains a significant risk factor for major cardiovascular events worldwide.
Poor adherence to treatment is extremely common in clinical practice, leading to …

The objective of this work was to investigate the long-term safety and efficacy of renal
denervation in Korean patients from the Global SYMPLICITY Registry (GSR). GSR Korea is …

Aims Several studies and registries have demonstrated sustained reductions in blood
pressure (BP) after renal denervation (RDN). The long-term safety and efficacy after RDN in …

Following the publication of the randomized controlled but open-label trial Symplicity HTN-2,
catheter-based renal sympathetic denervation was proposed as a novel treatment for drug …

Background: SYMPLICITY HTN-Japan is a prospective, randomized, controlled trial
comparing renal denervation (RDN) with standard pharmacologic therapy for treatment of …

Catheter-based renal denervation (RDN) has evolved recently as a promising minimally
invasive treatment for patients with hypertension, based on the concept of an old surgical …

Background Renal denervation has been shown to lower blood pressure in the presence of
antihypertensive medications; however, long-term safety and efficacy data from randomised …